Neurocrine price target lowered to $139 from $148 at RBC Capital
RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $139 from $148 and keeps a Sector Perform rating on the shares. The payer ...
Apple estimates lowered on tariffs, Siri update delay: Morgan Stanley
Morgan Stanley cuts Apple's EPS estimate & iPhone shipment forecast, citing tariff costs & delayed Siri AI upgrades.